# EnCare Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/encare-biotech-b-v

- Industry: Biotechnology
- Headquarters: Utrecht, Netherlands
- Website: www.encarebiotech.com
- Total disclosed funding: $6.8M
- Latest round: Series A (Nov 17, 2014)
- Investors on record: 2

## About

EnCare Biotech B.V. is a biotechnology firm focused on developing innovative biopharmaceuticals and diagnostic tools to enhance healthcare outcomes, particularly in oncology and infectious diseases.EnCare Biotech B.V. was founded in 2014 and operates out of Utrecht, Netherlands. The firm specializes in biotechnological solutions and has not undergone significant pivots in its business strategy. The company was initially established by a team with a background in biotech innovations. EnCare Biotech raised EUR 5.5 million in Series A funding on November 17, 2014, primarily from Index Ventures and Thuja Capital, totaling EUR 5.5 million raised to date.Encare Biotech specializes in developing and providing advanced biotechnological solutions aimed at enhancing healthcare outcomes. The company's core product offerings include a range of biopharmaceuticals and diagnostic tools designed to address specific health challenges, particularly in the fields of oncology and infectious diseases. These products are engineered to function by targeting disease mechanisms, thereby improving patient management and treatment efficacy. Encare Biotech serves a diverse client base, including hospitals, research institutions, and pharmaceutical companies, primarily in North America and Europe. The end users of these products are healthcare professionals and patients seeking innovative therapies that can lead to better health results.Encare Biotech generates revenue through a structured model involving direct sales and partnerships with healthcare providers and institutions. The company engages in B2B transactions, supplying its biopharmaceutical products and diagnostic tools to hospitals and clinics, which incorporate them into their treatment protocols. The pricing structure for these products reflects their specialized nature, with flagship offerings commanding premium prices due to their unique therapeutic benefits. Encare Biotech also explores collaborative agreements with larger pharmaceutical firms, allowing for shared research and development efforts, which can enhance their market reach and profitability. This multifaceted approach to revenue generation ensures a steady flow of income while expanding their presence in key geographical markets.EnCare Biotech plans to utilize the recent EUR 5.5 million raised in Series A funding to accelerate the development of new products targeting specific disease mechanisms in oncology and infectious diseases. The company aims to launch several new biopharmaceuticals by late 2025 and is actively exploring expansion into North American and European markets, enhancing its presence in these regions by establishing new partnerships and distribution agreements. This strategic approach is designed to bolster their market position and drive future revenue growth.

## Funding rounds

- Series A, Nov 17, 2014, $6.8M — Index Ventures, Thuja Capital

## Investors

- Index Ventures (https://capitalatlas.ai/funds/index-ventures) — Series A
- Thuja Capital (https://capitalatlas.ai/funds/thuja-capital) — Series A